Turn Therapeutics Announces Final Stage 2 Design and Expansion of GX-03 Phase 2 Trial

Turn Therapeutics Inc.

Interim analysis of GX-03 Phase 2 trial in atopic dermatitis showed Week 4 vIGA-AD Success 71.4% vs 33.3% vehicle in EASI 1.1-7.0 subgroup.
Final Stage 2 design will enroll 120-135 patients across full EASI spectrum (≥1.1) using Hochberg multiple testing procedure for four endpoints.
GX-03 demonstrated favorable safety with no treatment-related serious adverse events or discontinuations reported.
Company expects to complete enrollment in Q4 2026 and is capitalized through Q3 2027.
Turn Therapeutics hosted an investor webcast on July 7, 2026 at 4:30 PM ET to discuss the results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.